Tivdak for Recurrent Cervical Cancer

Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer

Recruiting Phase 4 Interventional Study
Cervical Cancer
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Female
Trial phase
Phase 4
Study type
Interventional
Purpose
Other
Participants needed
100 (estimated)
Sponsor
Pfizer · Industry
Who this trial is looking for

This trial is looking for patients with recurrent cervical cancer who have not received Tivdak before. Participants will receive an infusion of Tivdak every three weeks and undergo eye tests at specific times during the treatment.

Are You a Good Fit for This Trial?

You may be able to join if

  • I have recurrent or metastatic cervical cancer that has progressed after chemotherapy.
  • My doctor thinks Tivdak is a suitable treatment for me.
  • I can understand the purpose and procedures of the study.
  • I am willing to take the required eye tests.
  • I will use effective contraception.

You may not be able to join if

  • I have active eye issues.
  • I have received Tivdak before.
  • I have taken an investigational drug in the past 30 days.
  • I have any medical or psychiatric condition that poses a risk.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial
TIVDAK is used for the treatment of cervical cancer that has come back after chemotherapy. Chemotherapy is a treatment that uses medicines to stop the growth of cancer cells. This is done either by killing the cells or by stopping them from growing. The purpose of this study is to learn about possible side effects of TIVDAK, specially to any side effect that is related to the eye. A side effect is…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion criteria: 1. Must have recurrent or metastatic cervical cancer with disease progression on or after chemotherapy 2. Treating physician has determined that treatment with Tivdak is appropriate for the participant according to US Prescribing Information 3. Must sign an informed consent form…
Contacts

Pfizer CT.gov Call Center

1-800-718-1021

ClinicalTrials.gov_Inquiries@pfizer.com

CONTACT